....Wishing you a life full of good health and happiness....

September 19, 2010

Actos linked to bladder cancer: FDA

According to the Food & Drug Administration (FDA) type 2 diabetic drug "Actos" has  found to be linked to bladder cancer.

On Friday the U.S. FDA said that it is reviewing the type 2 diabetes drug Actos (pioglitazone), after its initial results found an increased risk of bladder cancer in patients with the longest exposure to pioglitazone & in those with the highest cumulative dose of the drug.

Pioglitazone is used along with diet & exercise to control blood sugar or improve control of blood sugar in patients with Type 2 Diabetes mellitus. Around 20 in every 100,000 Americans annually get bladder cancer, which is believed to be higher in people with diabetes.

The FDA noted that there is no concrete data that the drug increases the risk of bladder cancer. It was discovered that with the increased usage & duration of pioglitazone, the possibility of cancer boosted. After 24 months of continued use, the statistical significance in bladder cancer jumped significantly.

Pioglitazone is in the same class of drugs as GlaxoSmithKline PLC’s Avandia, which has not been associated with bladder cancer but has been linked to heart risks in some studies. Glaxo, however, has said overall scientific evidence does not show that the drug increases heart attack risk. In July, a panel of FDA advisers released a mixed verdict about whether Avandia should remain the market.

No comments:

Blog Ratings 5/5

 
© 2009 - Forever | KSRealityBites | Stalk Us on Facebook and Follow Us on Twitter | No Part of this site can be reproduced in whole or in part in any form or medium!